{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Pramlintide",
    "short_name": "Pramlintide",
    "aliases": [
      "symlin",
      "symlinpen",
      "amylin analog"
    ],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Classification describes what Pramlintide is and the general domain where it appears."
    },
    "status": {
      "category": "approved_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how Pramlintide appears in clinical literature and/or real-world contexts. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk scoring reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Pramlintide is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Pramlintide",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "needs_prescription": true,
    "meta": {
      "priority": "normal",
      "notes_seed": "FDA-approved pramlintide (Symlin) amylin analog (Rx) for glycemic control adjunct in diabetes; include only label-level indications; no protocols."
    },
    "topics": {
      "primary": [
        "topic_fat_loss_metabolism",
        "topic_hormonal_endocrine"
      ]
    },
    "slug": "pramlintide"
  },
  "canonical_name": "Pramlintide",
  "interactions": {
    "drug_classes": [
      "antidiabetics-insulin-glp1"
    ],
    "supplement_classes": [
      "glucose-lowering-supplements"
    ],
    "notes": []
  },
  "practical": {
    "bottom_line": "Pramlintide is a prescription amylin analog used with mealtime insulin in diabetes. It can meaningfully change appetite and gastric emptying, and hypoglycemia risk is real when combined with insulin.",
    "benefits": [
      "post-meal glucose control support in diabetes contexts (prescription use)",
      "reduced appetite and smaller meal size discussions (variable)",
      "sometimes discussed for modest weight support in supervised diabetes care"
    ],
    "side_effects_common": [
      "nausea",
      "reduced appetite",
      "fullness or bloating",
      "headache"
    ],
    "side_effects_serious": [
      "severe hypoglycemia when combined with insulin (confusion, fainting, seizure)",
      "severe persistent vomiting or dehydration",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "anyone not under medical supervision for diabetes management",
      "people with hypoglycemia unawareness or frequent severe lows",
      "people with gastroparesis or significant GI motility disorders",
      "pregnant or breastfeeding individuals",
      "adolescents (high-consequence glucose manipulation plus limited context)"
    ],
    "schema_version": "practical_block_v1"
  }
}
